SCHEMBL9333497

SCHEMBL9333497

COC(=O)c1cc(N)c(OC)c(OC)c1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TSHR P16473 2/20 0.56
▸ SMN1; SMN2 Q16637 1/20 0.56
▸ KDM4E B2RXH2 4/20 0.56
▸ POLB P06746 1/20 0.56
▸ TUBB4A P04350 1/20 0.55
▸ TUBB P07437 1/20 0.55
▸ TUBA3C P0DPH7 1/20 0.55
▸ TUBA1B P68363 1/20 0.55
▸ TUBA4A P68366 1/20 0.55
▸ TUBB4B P68371 1/20 0.55
▸ TUBB3 Q13509 1/20 0.55
▸ TUBB2A Q13885 1/20 0.55
▸ TUBB8 Q3ZCM7 1/20 0.55
▸ TUBA3E Q6PEY2 1/20 0.55
▸ TUBA1A Q71U36 1/20 0.55
▸ TUBA1C Q9BQE3 1/20 0.55
▸ TUBB6 Q9BUF5 1/20 0.55
▸ TUBB2B Q9BVA1 1/20 0.55
▸ TUBB1 Q9H4B7 1/20 0.55
▸ MAPT P10636 2/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5220471 0.89 KDM4E (0.56) TSHRSMN1; SMN2KDM4EPOLBTUBB4A
SCHEMBL1052202 0.87 SMN1; SMN2 (0.48) TSHRSMN1; SMN2KDM4EPOLBTUBB4A
Methyl Syringate SCHEMBL211747 0.87 MEN1 (0.61) TSHRSMN1; SMN2KDM4EPOLBTUBB4A
SCHEMBL28496437 0.84 TPMT (0.66) TSHRSMN1; SMN2TUBB4ATUBBTUBA3C
SCHEMBL18031417 0.84 KDM4E (0.53) TSHRSMN1; SMN2KDM4EPOLBTUBB4A
SCHEMBL7374627 0.84 LMNA (0.58) TSHRSMN1; SMN2TUBB4ATUBBTUBA3C
SCHEMBL31059012 0.84 LMNA (0.58) TSHRSMN1; SMN2TUBB4ATUBBTUBA3C
SCHEMBL30418756 0.84 KDM4E (0.53) TSHRSMN1; SMN2KDM4EPOLBTUBB4A
SCHEMBL751242 0.82 KDM4E (0.53) TSHRSMN1; SMN2KDM4EPOLBTUBB4A
SCHEMBL8040178 0.82 KDM4E (0.51) TSHRSMN1; SMN2KDM4EPOLBTUBB4A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025120168-A1 SULFONAMIDE DERIVATIVES AND USE THEREOF IN THE TREATMENT OF CRYPTOSPORIDIUM INFECTIONS INSTITUT NATIONAL DE RECHERCHE POUR L'AGRICULTURE, L'ALIMENTATION ET L'ENVIRONNEMENT (INRAE) (FR) 2025-06-12 — — WO disclosed
US-20230263155-A1 5-(1H-INDOL-3-YL)-OXAZOLE, -OXADIAZOLE AND -FURAN DERIVATIVES AS ENHANCERS OF SPERM MOTILITY SPERMATECH AS (NO) 2023-08-24 — — US disclosed
US-20230263155-A1 5-(1H-INDOL-3-YL)-OXAZOLE, -OXADIAZOLE AND -FURAN DERIVATIVES AS ENHANCERS OF SPERM MOTILITY SPERMATECH AS (NO) 2023-08-24 — — US disclosed
US-5358948-A Psychological, nervous system disorders GLAXCO GROUP LIMITED (GB) 1994-10-25 — — US disclosed
WO-1993006084-A1 BENZANILIDE DERIVATIVES AS 5-HT1D ANTAGONISTS GLAXO GROUP LIMITED (GB) 1993-04-01 — — WO disclosed
EP-0533267-A1 Benzanilide derivatives as 5-HT1D antagonists GLAXO GROUP LIMITED (GB) 1993-03-24 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230263155-A1 5-(1H-INDOL-3-YL)-OXAZOLE, -OXADIAZOLE AND -FURAN DERIVATIVES AS ENHANCERS OF SPERM MOTILITY NR5A1, NR1I3, NR5A2 TSHR 226/4885SMN1; SMN2 2799/4885KDM4E 3913/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback